EUVIMEDEUVIMED entdecken
Open Access · CC BYNC 3.0

Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial

William L Baker, Jeffrey Kluger, Craig I Coleman, C Michael White

The Open Cardiovascular Medicine Journal · 30.10.2015 · 9 (1) · 83-88

DOI: 10.2174/1874192401509010083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Open Cardiovascular Medicine Journal, erschienen am 30.10.2015. Verfasst von William L Baker und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Connecticut, Schools of Pharmacy, Hartford CT, USA; Storrs and Farmington, Hartford Hospital, Division of Pharmacy, Hartford CT, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BYNC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated the antiarrhythmic efficacy and quality of life (QoL) impact of oral magnesium Llactate on patients with an implantable cardioverter defibrillator (ICD).

Methods

This prospective, double-blind, placebo-controlled trial randomized 70 patients with an ICD to receive oral magnesium L-lactate 3 tablets twice daily (504mg elemental magnesium daily) or matching placebo for 12 months. Patients were seen at baseline, 12, 24, 36, and 52 weeks. The primary endpoints were the cumulative occurrence of ICD therapy [either shock or anti-tachycardia pacing (ATP)] or QoL between the groups.

Results

Among the 70 randomized patients with a mean ± SD follow-up of 6.4 ± 4.1 months, 10 patients in the placebo group and 8 in the magnesium group experienced either ICD shock or ATP [HR 0.84, 95% CI 0.33 to 2.12; p=0.706]. Without significant arrhythmia suppression, only minimal effects on QoL were seen. Eighty six percent of all patients had serum intracellular magnesium deficiency.

Conclusion

In our underpowered trial, patients with ICDs had intracellular magnesium deficiency but oral magnesium Llactate only nonsignificantly reduced the occurrence of ICD therapies and had little impact on HrQoL.

Schlagwörter

Stichwörter der Autor:innen

Magnesiumarrhythmiaimplantable cardioverter defibrillatorquality of life

Autor:innen und Institutionen

  • University of Connecticut, Schools of Pharmacy, Hartford CT, USA; Storrs and Farmington, Hartford Hospital, Division of Pharmacy, Hartford CT, USA.
  • University of Connecticut, Schools of Medicine, Hhartford CT, USA; Storrs and Farmington, Hartford Hospital, Division of Cardiology, Hartford CT, USA.

Zitieren

APA

Baker, W. L., Kluger, J., Coleman, C. I., & White, C. M. (2015). Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial. The Open Cardiovascular Medicine Journal, 9(1), 83-88. https://doi.org/10.2174/1874192401509010083

Vancouver

Baker WL, Kluger J, Coleman CI, White CM. Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial. The Open Cardiovascular Medicine Journal. 2015;9(1):83-88. doi:10.2174/1874192401509010083

BibTeX
@article{Baker2015,
  author = {Baker, William L and Kluger, Jeffrey and Coleman, Craig I and White, C Michael},
  title = {Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial},
  journal = {The Open Cardiovascular Medicine Journal},
  year = {2015},
  volume = {9},
  number = {1},
  pages = {83--88},
  doi = {10.2174/1874192401509010083}
}
Kostenlos starten →